Compare Quest Diagnostics Inc (DGX) vs Duolingo Inc (DUOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Duolingo Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Duolingo Inc trades at $133.52 (market cap $6.34B). The key difference: Quest Diagnostics Inc is far larger — about 4.1× Duolingo Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals.
| DGX | DUOL | |
|---|---|---|
Market Cap | $26.21B | $6.34B |
Sector | Health | Technology |
52-Week High | $238.50 | $369.19 |
52-Week Low | $173.49 | $90.03 |
Enterprise Value | $31.97B | $5.11B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Duolingo (DUOL) trades at $134.63, down 1.87% amid mixed signals. The stock shows strong fundamentals with impressive revenue growth from $369M in 2022 to $1.04B in 2025 and net income turning positive to $414M. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $134 and resistance at $138. Recent Q2 2026 earnings beat expectations with $0.66 EPS versus $0.604 expected, though Q3 revenue guidance disappointed investors.
The outlook remains cautiously optimistic with robust user growth and profitability metrics, but near-term pressure exists from decelerating booking growth and margin concerns. Analyst consensus is mixed with 30% buy ratings and a $121 price target below current levels. Key risks include monetization challenges despite user growth and increased competitive pressures in the education technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →
